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Abstract. Cancer/testis antigens melanoma-associated 
antigen 4 (MAGE-A4) and New York esophageal squamous 
cell carcinoma-1 (NY-ESO-1) are of clinical interest as 
biomarkers and present valuable targets for immunotherapy; 
however, they are poor prognostic markers in non-small cell 
lung cancer (NSCLC). In addition, myeloid derived suppressor 
cells (MDSCs) are recognized as a key element in tumor 
escape and progression. The aim of the present study was to 
investigate the diagnostic and prognostic value of MAGE-A4 
and NY-ESO-1, and their association with MDSCs in NSCLC 
samples. The expression levels of MAGE-A4 and NY-ESO-1, 
and the infiltration of MDSCs (CD33+), were analyzed by 
immunohistochemistry of 67 tissue samples from patients 
with NSCLC. Overall, 58.33% of the NSCLC squamous cell 
carcinoma tissues and 94.7% of adenocarcinoma tissues were 
positive for MAGE-A4. NY-ESO-1 expression was observed in 
52.78% of the squamous cell carcinoma tissues and 80% of the 
adenocarcinoma tissues. In primary adenocarcinoma tumor 
tissues, MAGE-A4 and NY-ESO-1 demonstrated a higher 
intensity of expression compared with the squamous cell carci-
noma tissues. A total of 33 (91.7%) squamous cell carcinoma 
and 19 (95.0%) adenocarcinoma specimens were positive for 
CD33. The expression of MAGE-A4 and NY-ESO-1 antigens 
and infiltration of MDSCs was associated with poor prognosis 
of patients with NSCLC. Further studies investigating the 
association between these findings and underlying molecular 
mechanisms are required.
Introduction
As the leading cause of cancer-associated death worldwide 
in 2018, lung cancer causes significant challenges for cancer 
researchers (1). Non-small cell lung cancer (NSCLC) is the 
most common type of lung cancer, accounting for ~85% of all 
cases (2). The long-term prognosis of patients with lung cancer 
is poor and the overall 5-year survival rate has been reported 
to be as low as 18% in USA according to the American Cancer 
Society (3).
Recent evidence of the clinical efficacy of immuno-
therapeutic approaches, including chimeric antigen receptor, 
T-cell therapy, immune checkpoint blockade and vaccine 
therapy (4-6), for lung cancer suggests that immunotherapy will 
become the next major therapeutic advance for this disease. 
Vaccines include antigen specific therapies, which induce 
specific antitumor immunity against relevant tumor‑associated 
antigens. The cancer/testis (CT) family of antigens, including 
melanoma-associated antigen 4 (MAGE-A4) and New York 
esophageal squamous cell carcinoma-1 (NY-ESO-1), has 
been a focus of previous studies (7,8) due to their potential as 
immunotherapeutic targets (9,10). Furthermore, experimental 
studies have shown the ability of CT antigens to elicit a 
specific cellular response, including cytotoxic T lymphocytes 
(CTLs), and humoral immune responses (9,11-14). The pres-
ence of high numbers of CTLs in the tumors of patients with 
NSCLC is associated with enhanced survival (15-17); however, 
contrasting results demonstrated that high expressions of CT 
antigens were associated with poor survival in patients with 
lung cancer (18,19). A possible reason for this may be the 
accumulation of myeloid derived suppressor cells (MDSCs) in 
peripheral lymphoid organs and tumor tissues (20,21).
MDSCs represent a heterogeneous population of immature 
myeloid cells that can strongly inhibit anti-tumor activities of 
T and NK cells and stimulate regulatory T cells (Treg), leading 
to tumor progression. Furthermore, MDSCs can contribute to 
patient resistance to immunotherapy (22,23). Several studies 
have examined the association between the MAGE-A4 and 
NY-ESO-1 expression levels and survival (18,24-29), as well 
as the association between the MDSCs infiltrated in the tumor 
microenvironment and the survival of patients with different 
types of lung cancer (30-33). However, the prognosis of the 
association between the MAGE-A4 or NY-ESO-1 and MDSCs 
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has yet to be confirmed. The present study aimed to disclose 
the association between the expression levels of MAGE-A4 or 
NY‑ESO‑1 and MDSCs infiltration in patients with NSCLC.
Materials and methods
NSCLC tissue selection. A total of 67 cases of NSCLC were 
retrieved from the archives of the Zibo Central Hospital 
between February 2010 and March 2015. The patients' records 
included clinical data, preoperative examination results, 
details of surgical operations, histopathological findings and 
Tumor Node Metastasis (TNM) staging (34). The preopera-
tive assessments included magnetic resonance imaging of the 
brain, bronchoscopy and bone scintigraphy. None of the 
patients underwent radiation or chemotherapy before surgery. 
The present study was approved by The Ethics Committee of 
Zibo Central Hospital (Zibo, China) in accordance with the 
Declaration of Helsinki and all procedures were approved 
by the Institutional Review Board of Zibo Central Hospital 
(Zibo, China). Tissue samples, including lung cancer speci-
mens and normal tissues adjacent to tumor, were collected 
after informed consent was provided by all patients. The 
histopathological subtype, stage and grade of the tumors were 
determined by four pathologists according to the guidelines 
of the World Health Organization Classification of Lung 
Tumors (The 2015 World Health Organization Classification 
of Lung Tumors) (35). For survival analysis, follow-up was 
also performed. Patient survival was calculated as the time 
between surgery and mortality. Patients who were still alive 
at the time of data collection were censored in the statistical 
analysis (Table I).
Immunohistochemistry (IHC). IHC was performed according 
to the following protocol. Briefly, 0.9% saline washed‑surgical 
resections were cut into 4 mm thickness and fixed with 10% 
formaldehyde overnight at room temperature. After dehydra-
tion with increasing concentration of ethanol (50, 70, 90 and 
100%) and cleaning with xylene, tissues were embedded with 
paraffin (36). Consecutive sections from paraffin‑embedded 
tissue blocks were cut into 4‑µm sections, deparaffinized and 
rehydrated with xylene and descending ethanol (100, 90, 70 
and 50%). Endogenous peroxidase activity was blocked by a 
10-min incubation with 0.3% hydrogen peroxide in methanol 
at room temperature. Epitope retrieval was performed using 
1 mM EDTA buffer (pH 8.0) in a microwave for 15 min, 
followed by cooling for 20 min at room temperature. Sections 
were washed with PBST and blocked with 10% normal goat 
serum (cat. no. G9023; Sigma-Aldrich; Merck KGaA) for 
30 min at room temperature. The expression of NY-ESO-1, 
MAGE-A4 and CD33 in lung cancer and normal tissues was 
detected by incubation with primary monoclonal antibodies 
against NY-ESO-1 (1:200; cat. no. 35-6200; Thermo Fisher 
Scientific, Inc.), MAGE‑A4 (1:150; cat. no. ab139297; Abcam) 
and CD33 (1:100; cat. no. 303402; BioLegend, Inc.) at 4˚C 
overnight. Sections were washed three times with PBST and 
were incubated with goat anti-mouse secondary antibody, 
HRP (1:2,000; cat. no. 62‑6520; Thermo Fisher Scientific, Inc.) 
for 1 h at room temperature. Sections were washed three times 
with PBST and were incubated with 5% 3,3-diaminobenzidine 
for 10 min at room temperature until brown colors developed. 
Slides were counterstained with hematoxylin and mounted on 
glass coverslips. Slides were viewed under bright field using an 
upright microscope BX63 (Olympus Corporation), and repre-
sentative areas were photographed using a CCD camera and 
processed using Olympus Image Analysis software (Olympus 
Stream 1.9; Olympus Corporation). The levels of MAGE-A4, 
NY-ESO-1 and CD33 expression were determined using a 
semi-quantitative four-grade scoring system (+, 5-25%; ++, 
25-49%; +++, 50-75%; ++++, >75% of cells stained). Focal 
staining of single cells or small clusters (<5% total) was consid-
ered as negative staining. There was no significant difference 
between the expression levels of MAGE-A4, NY-ESO-1 and 
CD33 in patients with NSCLC using the four-grade scoring 
system. Patients were therefore classified into positive and 
negative groups. The positive group included tissues stained 
from + to ++++. Individual core counts from five replicates 
were available for most cases.
Statistical analysis. IHC data was evaluated using a χ2 test. 
Pearson's correlation analysis was used to confirm the associa-
tion between variables. The Kaplan-Meier method was used to 
estimate the probability of survival and survival differences 
were analyzed using a log-rank test. The receiver operating 
characteristic (ROC) curve was used to determine the optimal 
cut‑off values for the sensitivity and specificity of both CT 
antigens and CD33 in NSCLC prognosis. P<0.05 was consid-
ered to indicate a statistically significant difference. Statistical 
analyses were performed using SPSS version 10.0 software 
(SPSS, Inc.).
Results
Clinicopathological parameters. The clinicopathological 
characteristics of the 67 patients with lung cancer included 
in this study are summarized in Table I. The average age of 
patients was 66 years (age range, 38-79 years). Patients included 
51 men (76.12%) and 16 women (23.88%). Pathologically, 36 
(53.73%), 20 (29.85%), 11 (16.42%) patients were diagnosed 
with squamous cell carcinoma (SCC), adenocarcinoma, and 
other pathologies than adenocarcinoma or SCC, including 
composite large-cell neuroendocrine carcinoma and squa-
mous cell carcinoma, composite large-cell carcinoma and 
squamous cell carcinoma, composite clear cell carcinoma and 
squamous cell carcinoma, large cell (undifferentiated) carci-
noma and adenosquamous carcinoma. The pathological stages 
were at Ia, Ib, IIa, IIb and IIIa in 11, 38, 12, 5 and 1 patients, 
respectively. Clinical follow-up was available for all cases. The 
median follow-up period was 48 months (range, 6-89 months).
MAGE‑A4, NY‑ESO‑1 and CD33 are upregulated in NSCLC 
tissues according to IHC. Expression levels of MAGE-A4 
and NY-ESO-1 in NSCLC specimens (specially focusing on 
squamous cell carcinoma and adenocarcinoma) were analyzed 
using IHC staining. To evaluate the immune suppressor cells 
infiltrating the tumor microenvironment, CD33 was detected 
using IHC. Furthermore, no staining of normal tissue adjacent 
to the positively stained tumors was detected (Fig. 1). The 
semi-quantitative results of immunohistochemical staining 
with MAGE-A4, NY-ESO-1 and CD33 monoclonal antibodies 
are shown in Tables II-V.
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In terms of MAGE-A4, 71.4% of NSCLC tissues demon-
strated positive staining. According to the histological types, 
the positive expression rates of MAGE-A4 in patients with 
squamous cell carcinoma and adenocarcinoma were 58.33 
and 94.7% (P=0.004), respectively (Table II). Regarding 
NY-ESO-1, NSCLC tissues demonstrated relatively low posi-
tive staining (62.5%). Considering the histological types, the 
positive expression rates of NY-ESO-1 were 52.78% in squa-
mous cell carcinoma samples and 80% in adenocarcinoma 
samples (P=0.04; Table II). The MAGE-A4 and NY-ESO-1 
double expression rate was 70% in adenocarcinoma tissues, 
which was significantly higher compared with the expression 
rate in squamous carcinoma (38.89%; P=0.026; Table III). In 
each histological type, tumor differentiation was associated 
with the expression of MAGE-A4 and NY-ESO-1 antigens. As 
shown in Table II, 92.90% of NSCLC tissues were positive 
for CD33 expression. The positive expression rates of CD33 in 
squamous cell carcinoma and adenocarcinoma were 91.7 and 
95.0% (P=0.6; Table II).
According to sex, the MAGE-A4-positive expression rate 
was significantly higher in women (84.6%) compared with 
men (65.1%; P<0.01; Table IV). NY-ESO-1 also demonstrated 
a greater expression in females compared with males (69.2 vs. 
53.5%; P<0.05; Table IV). As for CD33, there was a similar 
expression rate in women (84.6%) and men (90.1%). The 
expression of both CT antigens and CD33 in NSCLCs was 
not correlated with patients age, TNM-pT and stage (data not 
shown).
Association between MDSC infiltration and combined 
patterns of CT antigens expression. A total of four combined 
expressions of MAGE-A4 and NY-ESO-1 were evaluated to 
determine the association with MDSC infiltration (Table III). 
Combined positive expression for CD33, NY-ESO-1 and 
MAGE‑A4 was significantly higher in adenocarcinoma tissues 
(55.00%) compared with squamous carcinoma tissues (36.11%; 
P=0.171). The double expression rates of CD33/MAGE-A4, 
CD33/NY-ESO-1 and MAGE-A4/NY-ESO-1 were higher in 
squamous cell carcinoma compared with adenocarcinoma 
tissues (Table III). A χ2 test was used to analyze the association 
between MAGE-A4 and NY-ESO-1 expression and between 
CT antigens and CD33 expression. The group with positive 
MAGE-A4 or NY-ESO-1 staining demonstrated a higher 
number of infiltrating MDSCs compared with the groups 
with negative MAGE-A4 or NY-ESO-1 expression (P<0.005; 
Table V). In addition, the expression levels of both CT anti-
gens in NSCLC were correlated (Pearson's r=0.411; P=0.002; 
Table V).
The association between the CT antigens expression and 
CD33 was analyzed using a χ2 test. There was no significant 
association between CT antigens expression and MDSC 
infiltration, although CD33 was expressed more frequently in 
CT antigens patients with positive expression compared with 
patients with negative expression (Tables III and V).
Prognostic value of MAGE‑A4, NY‑ESO‑1 and CD33 
expression. By using log-rank test, CD33 expression was 
significantly associated with survival rate (P=0.03; Fig. 2A). 
MAGE-A4 and NY-ESO-1 expression levels were identi-
fied to be significantly associated with prognosis in terms 
of survival rate (Fig. 2B and C; P=0.005 and P=0.001, 
respectively). Subsequently, tissues were classified based on 
pathological type to examine the prognostic value of CT anti-
gens and MDSC infiltration. By contrast, no association was 
identified between histology type and survival rate in patients 
positive in both CT antigen expression and CD33 expres-
sion (Fig. 2D-F), although there was a higher expression 
of CT antigens in adenocarcinoma compared with patients 
with squamous cell cancer (Table II; MAGE-A4, 58.33% 
positive expression in squamous cell cancer and 94.7% in 
Table I. Clinicopathological parameter of patients with primary 
non-small cell lung cancer.
Parameter n %
Total  67a 
Age, years  
  >60  51 76.12
  ≤60 16 23.88
  Median (range) 66 (38-79) 
Sex  
  Male 51 76.12
  Female 16 23.88
Histology  
  Squamous cell carcinoma 36 53.73
  Adenocarcinoma 20 29.85
  Other 11 16.42
pT status  
  pT1a 19 28.36
  pT1b 34 50.75
  pT2a 8 11.94
  pT2b 5 7.46
  pT3 1 1.49
  Unknown  
pN status  
  pN0 51 76.12
  pN1 16 23.88
Systemic metastasis (before operation)  
  No metastasis 67 100
Stage  
  Ia 11 16.42
  Ib 38 56.72
  IIa 12 17.91
  IIb 5 7.46
  IIIa 1 1.49
Grade  
   Well-differentiated 8 11.94
   Moderately differentiated 13 19.40
   Poorly differentiated  46 68.66
   Unknown  
Median follow-up (range), months 48 (6-89) 
aOne case missed their follow-up.
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adenocarcinoma; NY-ESO-1, 52.78% positive expression in 
squamous cell cancer and 80% in adenocarcinoma).  These 
results demonstrated that a poor prognosis was associated 
with positive CT antigen and CD33 expression in patients 
with squamous cell cancer and adenocarcinoma.
Prognostic value of MDSCs in patients with MAGE‑A4 or 
NY‑ESO‑1‑positive expression. In order to evaluate the asso-
ciation between MDSCs and prognosis in patients positively 
expressing CT antigens, the associated between the CT anti-
gens expression and the infiltration of MDSCs into the tumor 
site was analyzed (Fig. 3). In tissues positive for MAGE-A4, 
there was a significant difference between CD33-positive 
expression and CD33-negative expression in terms of survival 
rate (P=0.013; Fig. 3A). Compared with CD33-positive expres-
sion, the survival rate of patients with negative CD33-negative 
staining was improved, whereas there was no significant 
difference survival rate between in NY-ESO-1-positive and 
NY-ESO-1-negative cases (P=0.054; Fig. 3B). For further 
analysis of the sensitivity and specificity of both CT antigens 
and CD33 in NSCLC prognosis, a receiver operating charac-
teristic (ROC) curve was used to analyze the present results. 
The area under the ROC curve was 0.60, 0.626 and 0.721 for 
expression of MAGE-A4, NY-ESO-1 and CD33, respectively 
(Fig. 4).
Discussion
The evidence of clinical efficacy for immunotherapeutic 
approaches for lung cancer suggests that immunotherapy 
will become the next major therapeutic advance for this 
disease (5,37,38). NSCLC has historically been considered as 
a nonimmunogenic disease (2). Previous data has shown that 
much of this lack of immune responsiveness to lung cancer is 
due to high expression of CT antigens, which are expressed 
in the normal testis and placenta, but may also be expressed 
in tumor tissues (39-44). Thus, it is essential to determine 
the association between expression levels of CT antigens and 
prognosis of patients with lung cancer. In the present study, 
the expression of MAGE-A4 and NY-ESO-1 was analyzed 
by immunohistochemistry of 67 tissue samples from patients 
with NSCLC, and the survival of these patients was assessed. 
Patients with high expression of both CT antigens exhib-
ited a poor prognosis, which was consistent with previous 
studies (19,43,45). This may be due to the immunosuppressive 
microenvironment of the tumor (19). Regardless of the fact that 
MAGE and NY-ESO-1 can trigger a strong immune reaction 
by stimulating lymphocyte migration into the tumor microen-
vironment, these T cells do not readily translate to tumor cell 
killing in vivo (9,19).
Tumor infiltrating lymphocytes are important factors in 
the antitumor immune response, which are associated with 
cancer incidence, tumor growth, response to therapy and the 
prognosis of the disease (46). Intensive infiltration of CTLs 
into the tumor nest is associated with good patient prognosis 
in several tumor types (47‑51). Tumor‑specific CTLs recog-
nizing MAGE-A4 and NY-ESO-1 have been reported and 
several CTL epitopes within MAGE and NY-ESO-1 proteins 
have been identified (9,52,53). However, the present study 
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Table III. Combined positive expression of cancer/testis antigens MAGE-A4 and NY-ESO-1 and CD33.
  CD33/MAGE-A4/ CD33/MAGE-A4 CD33/NY-ESO-1 MAGE-A4/NY-ESO-1
Histology n NY-ESO-1 n (%) n (%) n (%) n (%)
Squamous cell carcinoma 36 13 (36.11) 18 (50) 17 (47.22) 14 (38.89)
Adenocarcinoma 20 11 (55) 15 (75) 11 (55) 14 (70)
P-value 0.171 0.068 0.5778 0.026
MAGE-A4, melanoma-associated antigen 4; NY-ESO-1, New York esophageal squamous cell carcinoma-1.
Table IV. CT antigens, CD33 expression and clinicopathologic parameters in NSCLC.
 MAGE-A4 NY-ESO-1 CD33
 ----------------------------------------------------------------- ----------------------------------------------------------------- -----------------------------------------------------------------
Sex n Negative n (%) Positive n (%) Negative n (%) Positive n (%) Negative n (%) Positive n (%)
Male 43 15 (34.9) 28 (65.1) 20 (46.5) 23 (53.5) 4 (9.1) 39 (90.1)
Female  13 2 (15.4) 11 (84.6) 4 (30.8) 9 (69.2) 2 (15.4) 11 (84.6)
P-value   <0.01  <0.05  
MAGE-A4, melanoma-associated antigen 4; NY-ESO-1, New York esophageal squamous cell carcinoma-1.
Figure 1. Immunohistochemical findings for MAGE‑A4, NY‑ESO‑1 and CD33 in non‑small cell lung cancer tissues. Specimens from the normal lung were 
used as a negative control. Staining of the normal lung demonstrated no reactivity for (A) CD33, (B) MAGE-A4 and (C) NY-ESO-1. Expression of (D) CD33, 
(E) MAGE‑A4 and (F) NY‑ESO‑1 in squamous cell carcinoma. Expression of (G) CD33, (H) MAGE‑A4 and (I) NY‑ESO‑1 in adenocarcinoma. Magnification, 
x100. MDSCs, myeloid derived suppressor cells; MAGE-A4, melanoma-associated antigen 4; NY-ESO-1, New York esophageal squamous cell carcinoma-1.
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MAGE-A4 or NY-ESO-1 and a poor prognosis in patients with 
NSCLC. One possible explanation for this apparent contradic-
tion may be some association with suppressive immune cells, 
including MDSCs (54,55).
The immune system plays a paradoxical role in the response 
to tumors by either preventing tumor growth or by permitting 
tumor escape and stimulating tumor development (7). MDSCs 
are a group of immature immune cells, which normally are 
not found in the circulation but accumulate in the blood and 
tumor of patients with cancer (56,57). MDSCs are involved in 
immune evasion of tumors (21). The importance of MDSCs in 
cancer-related immunosuppression is evident by the inhibitory 
effect on T cell proliferation and function and the fact that 
removal of MDSCs can restore T cell effector function (58,59). 
Until now, the role of MDSCs in the expression of MAGE-A4 
or NY-ESO-1 has remained elusive. Thus, the present study 
aimed to address the integrated relationship among the expres-
sion level of MAGE-A4 and NY-ESO-1, overall survival and 
infiltration of MDSCs into the tumor site in patients with 
NSCLC.
The positive frequency of MAGE-A4, NY-ESO-1 and CD33 
expression in NSCLC in present study was higher than that in 
previous studies (28,60). Notably, MAGE-A4 and NY-ESO-1 
were more highly expressed in adenocarcinoma compared 
with in squamous cell carcinoma tissues. These results 
are inconsistent with previous research (61). Intra-tumoral 
heterogeneity may partly explain the different extent to which 
certain CT antigens were re-expressed in tumors in the present 
study compared with previous work (62,63). In addition, 
discrepancies between RNA and protein expression levels are 
not uncommon and may contribute to the variety of expres-
sion levels reported (64); however, the association between 
CT antigen expression and disease development and tumor 
malignancy remains unclear, including NSCLC (65-69). It has 
been hypothesized that there is no association between the 
expression of CT antigens and sex (70,71); however, the present 
study demonstrated that a higher proportion of NSCLC tissue 
samples from female patients stained positive for CT antigens 
compared with samples from males. The genes that encode 
MAGE-A4 and NY-ESO-1 map to the X chromosome and 
are referred to as CT-X genes (62,72). This may be indica-
tive of the association of CT antigens with the female sex 
and could be associated with a dominance of female patients 
within adenocarcinoma group showing a higher expression 
of CT antigens (73-76). Regarding cancer stage, CT antigen 
expression patterns are associated with disease stage and 
no expression of CT antigens has been observed in benign 
tissues (64). However, the present study demonstrated a weak 
association between tumor stage and the expression of both 
CT. The possibility may be not at advanced stage with these 
observed samples.
As for survival, the high expression of MAGE-A4 and 
NY-ESO-1 was a prognostic marker for a less favorable prog-
nosis in patients with NSCLC. These results were indicative of 
a possible role of MAGE-A4 and NY-ESO-1 in determining 
greater malignant potential in types of lung cancer, although 
the underlying mechanism of function of these CT antigens 
in tumor biology has not been fully elucidated. The poor 
prognostic association of MAGE-A4 and NY-ESO-1 in lung 
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of these CT antigens may be a potential novel treatment for 
patients with NSCLC.
There was no clear association between MDSCs infiltra-
tion and MAGE-A4 or NY-ESO-1-positive expression in 
the present study and the results were inconsistent with our 
previous animal experiment (77). This may be explained by 
variation among species, different immunohistochemical 
sensitive antibodies depending on laboratory conditions and 
tumor cell heterogeneity. Previously, ROC curve analysis was 
used to assess diagnostic tests, which could also be used to 
assess predictive models (78-82). Limited by sample size, 
the ROC curves in the present study were based on patient 
survival without a series of cut-off points. The results indi-
cated that MAGE-A4, NY-ESO-1 and CD33 expression were 
better markers of the prognosis of patients with NSCLC.
When analyzing the prognosis in different pathological 
types, squamous cell cancer and adenocarcinoma, there was 
no significant difference in survival between these two patho-
logical types; however, MAGE-A4 and NY-ESO-1 expression 
had a significant difference in expression between squamous 
Figure 2. Survival analysis of patients with lung cancer. Patients with squamous cell cancer and adenocarcinoma were analyzed by Kaplan-Meier method. 
Pair-wise differences were analyzed using the log-rank test. (A) CD33 expression and survival rate. (B) MAGE-A4 expression and survival rate. (C) NY-ESO-1 
expression and survival rate. (D) MAGE-A4-positive expression and survival rate for patients with SCC or adenocarcinoma. (E) NY-ESO-1-positive expression 
and survival rate for patients with SCC or adenocarcinoma. (F) CD33-positive expression and survival rate for patients with SCC or adenocarcinoma. SCC, 
squamous cell cancer; MAGE-A4, melanoma-associated antigen 4; NY-ESO-1, New York esophageal squamous cell carcinoma-1.
Figure 3. Survival analysis of patients with lung cancer with positive MAGE-A4 and NY-ESO staining based on positive or negative CD33 expression. Data 
were analyzed by Kaplan-Meier method. Pair-wise differences were analyzed using the log-rank test. (A) CD33 expression and survival rate for patients with 
positive expression of MAGE-A4. (B) CD33 expression and survival rate for patients with positive expression of NY-ESO-1. MAGE-A4, melanoma-associated 
antigen 4; NY-ESO-1, New York esophageal squamous cell carcinoma-1.
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cell cancer and adenocarcinoma. A possible reason for this 
may be that the similar expression rate of CD33 in squamous 
cell cancer and adenocarcinoma (83). The present results 
indicated that higher CD33 expression levels were correlated 
with poorer prognosis. Given MDSC inhibition of T cells 
activation in a nonspecific or antigen‑specific manner (22,23), 
altering the dendritic cell peptide presenting ability of the 
major histocompatibility complex class I molecules on tumor 
cells (24,25), the functional analysis of CD8+ T cells might 
help understanding how MDSC could undermine the activity 
of CD8+ T cells within tumor nests. (22,84).
The limitations of the present study should be noted. The 
sample size was small, as all data were obtained from 67 cases. 
Due to the heterogeneity in patients with lung cancer, survival 
may be affected by histology and staging. In present study, 
the survival of patients with squamous cell carcinoma and 
adenocarcinoma was analyzed. In our previous experiment, 
we found that tumor infiltrating MDSCs enhanced the expres-
sion of MAGE-A4 in an animal model (77). Thus, the purpose 
of present study was to investigate the association between 
the expression levels of MAGE-A4 or NY-ESO-1 and MDSCs 
infiltration in patients with NSCLC. Once there is positive 
or negative correlation between CT antigens expression and 
MDSCs the molecule and pathway which affects the protein 
expression should be investigated which may then be beneficial 
to cancer therapy. Given the immunogenicity of CT antigen 
and immune suppression of MDSC, CT antigen expression 
can be upregulated, which would induce anti-tumor immune 
response and MDSCs be downregulated, which would attenuate 
MDSCs-induced immunosuppression. However, the present 
study was limited by the sample size and no such correlation 
was observed, although there was a tendency to some degree 
between CT antigens expression and MDSC infiltrating in 
tumor microenvironment. In future research, considering that 
larger sample sizes produce more reliable results with greater 
precision and power (85-87), the study population should 
consist of long-surviving and short-surviving patients with 
NSCLC and the correlation between CT antigens expression 
and CTL infiltration or between CTL and MDSC infiltrations 
should be investigated.
In conclusion, the poor prognosis of patients with NSCLC 
with MAGE-A4 and NY-ESO-1 expressing tumors with high 
infiltrating MDSCs suggests that the spontaneous immune 
response is not sufficient against these antigens. The devel-
opment of a combination therapy is required for patients 
with NSCLC with tumors expressing CT antigens, such as 
vaccinating with MAGE-A4 and NY-ESO-1 recombinant 
proteins or peptides. In addition, this combination therapy 
should combine with an inhibitor targeting CD33 to reduce 
the suppressive MDSCs.
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of patients with non-small cell lung cancer. The area under the curve for 
MAGE-A4, NY-ESO-1 and CD33 was 0.600, 0.626 and 0.721, respectively. 
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